Valneva SE American Depositary Shares
VALN Real Time Price USDRecent trades of VALN by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in VALN holdings by institutional investors
Quarterly net insider trading by VALN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for VALN
22 former government officials from 11 congressional offices at 6 lobbying firms have lobbied for VALN, most recently Apr 20, 2026.
-
Raissa Downs Senate Prin. Dep. Asst. Sec for Leg.-HHS; Dep. Asst. Sec. for Leg.-HSS; Staff Dir., Sub Cmte. on Employment, Sen. HELP Cmte.
-
Jennifer Young Congress Asst. Sec. for Leg.- HHS; Dep. Asst. Sec for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff. Sen. Cmte. on Finance
-
Elizabeth Murray House Senior Policy Advisor, Democratic Whip Steny Hoyer; Leg. Asst., Rep. Mike Thompson, Rep. Bob Matsui, and Sen. Bob Graham -
Pamela Smith Senate Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Sen. HELP Cmte.; Staff Dir., Sen. HELP Cmte.; Counsel to Asst. AG, Civil Div., Dept. of Justice; Spec. Counsel, Ofc of Leg. Affairs, Dept. of Justice; Counsel and LA, Sen. Carol Moseley-Braun -
Margaret Joseph Senate CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte. -
Parick Carroll House Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin Yoder, PSM Senate Appropriations Cmte. -
Laura Friedel Senate Leg. Asst., Sen. Zell Miller, Leg. Dir., Sen. Richard Shelby, Clerk, Staff Dir., Sen. Appropriations Committee -
Charlotte Ivancic Senate Leg. Counsel, Sen. Jim DeMint; Health Counsel, Maj. Leader Bill Frist; Counsel and Budget Analyst, House Budget Cmte.; Asst. to the Speaker for Policy, Speaker John Boehner
VALN Estimated quarterly lobbying spending
VALN Revenue by Segment or Geography
New VALN patent grants
-
Patent Title: Single shot chikungunya virus vaccine Apr. 21, 2026
-
Patent Title: Chikungunya vaccine formulations Apr. 21, 2026
-
Patent Title: Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-δ5nsp3 Mar. 03, 2026
-
Patent Title: Virus purification Feb. 04, 2025
-
Patent Title: Subunit vaccine for treatment or prevention of a respiratory tract infection Dec. 10, 2024
-
Patent Title: Subunit vaccine for treatment or prevention of a respiratory tract infection Dec. 10, 2024
-
Patent Title: Method for rescuing and producing a virus in avian cells Aug. 06, 2024
-
Patent Title: Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 Jun. 18, 2024
-
Patent Title: Aseptic purification process for viruses Apr. 18, 2023
-
Patent Title: Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 Nov. 01, 2022
-
Patent Title: Virus purification Aug. 09, 2022
-
Patent Title: Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5np3 Jun. 14, 2022
-
Patent Title: Virus purification Dec. 28, 2021
-
Patent Title: Aseptic purification process for viruses May. 26, 2020
-
Patent Title: Virus purification May. 26, 2020
-
Patent Title: Virus purification Jan. 21, 2020
-
Patent Title: Method of making a virus using duck embryonic derived stem cell lines Nov. 21, 2017
-
Patent Title: Production of viral vaccines in suspension on avian embryonic derived stem cell lines Jul. 11, 2017
-
Patent Title: Method of making an avian cell line Jul. 05, 2016
-
Patent Title: Microwell array chip and method of manufacturing same Apr. 12, 2016
-
Patent Title: Generation of duck cell lines Feb. 16, 2016
-
Patent Title: Method of screening by using conformation sensitive peptides Nov. 10, 2015
-
Patent Title: Production of viral vaccines in suspension on avian embryonic derived stem cell lines May. 26, 2015
-
Patent Title: Method of obtaining chicken embryonic stem cells Feb. 24, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to VALN from public contracts
Recent insights relating to VALN
Recent picks made for VALN stock on CNBC
ETFs with the largest estimated holdings in VALN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $VALN stock a Buy, Sell, or Hold?
- What is the price target for $VALN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $VALN stock?
- Who owns the most shares of $VALN stock?
- What funds own $VALN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VALN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Valneva SE American Depositary Shares (VALN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Valneva SE American Depositary Shares (VALN).
Quiver Premium charts VALN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at VALN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|